In 2020, Selecta reported that SEL-212 wasn’t able to show superiority over Krystexxa on the primary endpoint of maintaining uric acid in the blood levels under 6 mg/dL for at least 80% of the ...

This week's round-up of new financings in the biotech world is headed by a big round for Third Arc, a specialist in T-cell engager antibodies, with Autobahn, Brenig, Confo, and GRO Bio also in on ...

Abstract—The question of serum uric acid as an independent risk factor in subjects with essential hypertension remains controversial. For up to 12 years (mean, 4.0) we followed 1720 subjects with ...